Teladoc Health
Teladoc Health's revenue fell 1.5% to $2.5 billion in fiscal 2025. Its operating margin was −10.4%, up from −39.7% a year earlier. Free cash flow was $285 million, up 0.9%. The diluted share count rose 3.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Teladoc Health does
Teladoc Health provides virtual care: doctor and therapy visits by video, phone, app and text. It sells to employers, health insurers, hospitals and health systems, and also directly to consumers. It says it completed 17.1 million telehealth visits in 2025 across its business and consumer channels.
It reports two segments. Integrated Care sells mostly to employers and insurers, and gives members access to services such as primary care, urgent care, mental health, chronic condition care and expert second opinions. For hospitals and health systems it also sells hardware, software and services for telehealth. BetterHelp is its online counseling and therapy service, which uses a network of nearly 35,000 licensed clinicians.
The company says it uses data, AI and human expertise to guide members to the care they need, and refers them to in-person care when appropriate.
Its biggest risks, as it describes them
- It has a history of cumulative losses and may never reach lasting profitability.
- A large part of its revenue comes from a few clients, and losing one could hurt it badly.
- It may have to write down the value of goodwill and other intangible assets, which would reduce its reported results.
- The virtual care market may grow more slowly than expected or its services may not draw enough member use.
- It pays large upfront costs to win clients and may not earn them back if clients leave.
Income statement
Teladoc Health lost money in fiscal 2025: a net loss of $200 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 896 | 918 | 1,124 | 1,298 | 781 |
| Debt incl. finance leases | 1,226 | 1,535 | 1,539 | 1,542 | 995 |
| Net debt (negative means net cash) | 330 | 617 | 415 | 244 | 214 |
| Net debt to EBITDA | — | — | 4.7x | — | 2.1x |
| Debt to equity | 0.1x | 0.7x | 0.7x | 1.0x | 0.7x |
| Interest coverage | −3.3x | −622.2x | −11.2x | −42.9x | −13.3x |
| Current ratio | 3.7x | 3.3x | 3.5x | 1.8x | 2.8x |
| Quick ratio | 3.5x | 3.1x | 3.5x | 1.7x | 2.7x |
Cash flow
Projections
Project Teladoc Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $69,400 of Teladoc Health shares on the open market, and 6 insiders sold $2.4 million, $493,821 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Charles Divita IIIChief Executive Officer, Director | Sold | 17,805 | $6.10 | $108,610 | Form 4 |
| Sep 3, 2026 | Fernando M. RodriguesPresident of BetterHelp | Sold plan | 9,812 | $6.51 | $63,876 | Form 4 |
| Sep 2, 2026 | Charles Divita IIIChief Executive Officer, Director | Sold | 18,327 | $6.30 | $115,460 | Form 4 |
| Sep 2, 2026 | Adam C VandervoortChief Legal Officer, Secretary | Sold | 7,573 | $6.30 | $47,710 | Form 4 |
| Sep 2, 2026 | Kelly BlissPresident, U.S. Group Health | Sold | 7,357 | $6.30 | $46,349 | Form 4 |
| Sep 2, 2026 | Carlos NuenoPresident, International | Sold | 6,200 | $6.30 | $39,060 | Form 4 |
| Sep 2, 2026 | Fernando M. RodriguesPresident of BetterHelp | Sold plan | 5,439 | $6.30 | $34,266 | Form 4 |
| Sep 2, 2026 | Joseph Ronald CatapanoChief Accounting Officer | Sold | 274 | $6.30 | $1,726 | Form 4 |
| Jul 6, 2026 | Kelly BlissPresident, U.S. Group Health | Sold plan | 2,500 | $9.50 | $23,750 | Form 4 |
| Jul 2, 2026 | Joseph Ronald CatapanoChief Accounting Officer | Sold | 653 | $9.10 | $5,942 | Form 4 |
| Jul 1, 2026 | Kelly BlissPresident, U.S. Group Health | Sold plan | 2,500 | $9.00 | $22,500 | Form 4 |
| Jun 29, 2026 | Kelly BlissPresident, U.S. Group Health | Sold plan | 2,500 | $8.50 | $21,250 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 8 | 2 of 8 | 6 of 8 |
| Rule of 40 | 21.1% | 9.8% | 9.7% |
| Altman Z'' | −8.91 | −14.88 | −16.73 |
| Accruals ratio | −13.1% | −32.8% | −15.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 5 of 8 | 2 of 8 | 6 of 8 |
Compare
Put Teladoc Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Teladoc Health | FY25 | −1.5% | −10.4% | 11.3% | −12.5% | 2.1x | 6 | |
| Chemed | FY25 | 4.1% | 13.4% | 12.9% | 27.3% | −0.2x | 5 | Compare |
| Aveanna Healthcare | FY25 | 20.2% | 10.5% | — | 21.6% | 4.1x | 7 | Compare |
| Hims & Hers Health | FY25 | 59.0% | 4.5% | 2.5% | 19.0% | 2.5x | 4 | Compare |
| Amn Healthcare Services | FY25 | −8.5% | −2.0% | 8.6% | −2.8% | 7.2x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 123 | 233 | 418 | 553 | 1,094 | 2,033 | 2,407 | 2,602 | 2,570 | 2,530 |
| Revenue growth | 59.1% | 89.4% | 79.1% | 32.4% | 97.7% | 85.8% | 18.4% | 8.1% | −1.3% | −1.5% |
| Gross profit | 91 | 172 | 289 | 369 | 703 | 1,382 | 1,663 | — | — | — |
| Research and development | 22 | 34 | 54 | 65 | 165 | 312 | 334 | 348 | 307 | 278 |
| Operating income | −63 | −75 | −71 | −80 | −506 | −266 | −13,653 | −249 | −1,021 | −263 |
| Net income | −74 | −107 | −97 | −99 | −485 | −429 | −13,660 | −220 | −1,001 | −200 |
| Diluted EPS (US$) | −1.75 | −1.93 | −1.47 | −1.38 | −5.36 | −2.73 | −84.60 | −1.34 | −5.87 | −1.14 |
| Diluted shares (millions) | 42 | 55 | 66 | 72 | 90 | 157 | 162 | 165 | 171 | 176 |
| Cash flow | ||||||||||
| Cash from operations | −52 | −34 | −5 | 30 | −54 | 194 | 189 | 350 | 294 | 294 |
| Capital expenditure | 2 | 3 | 4 | 4 | 4 | 8 | 16 | 12 | 11 | 9 |
| Free cash flow | −54 | −37 | −9 | 26 | −58 | 185 | 173 | 339 | 283 | 285 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 37 | 379 | 282 | 11 | 567 | 79 | 0 | 0 | 0 | 82 |
| Stock-based compensation | 8 | 31 | 44 | 67 | 476 | 303 | 218 | 202 | 146 | 80 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 50 | 43 | 478 | 517 | 787 | 896 | 918 | 1,124 | 1,298 | 781 |
| Debt incl. finance leases | 44 | 207 | 415 | 440 | 1,422 | 1,226 | 1,535 | 1,539 | 1,542 | 995 |
| Total assets | 304 | 824 | 1,529 | 1,603 | 17,755 | 17,735 | 4,345 | 4,392 | 3,516 | 2,858 |
| Total liabilities | 73 | 266 | 516 | 589 | 1,872 | 1,689 | 2,038 | 2,066 | 2,025 | 1,473 |
| Shareholders' equity | 231 | 559 | 1,013 | 1,014 | 15,884 | 16,046 | 2,308 | 2,326 | 1,491 | 1,386 |
| Margins and ratios | ||||||||||
| Gross margin | 74.0% | 73.6% | 69.2% | 66.7% | 64.3% | 68.0% | 69.1% | — | — | — |
| Operating margin | −50.9% | −32.3% | −16.9% | −14.5% | −46.3% | −13.1% | −567.3% | −9.6% | −39.7% | −10.4% |
| Net margin | −60.3% | −45.8% | −23.2% | −17.9% | −44.4% | −21.1% | −567.5% | −8.5% | −39.0% | −7.9% |
| Free cash flow margin | −43.8% | −15.9% | −2.1% | 4.8% | −5.3% | 9.1% | 7.2% | 13.0% | 11.0% | 11.3% |
| Rule of 40 (growth + FCF margin) | 15.3% | 73.5% | 77.0% | 37.2% | 92.5% | 94.9% | 25.6% | 21.1% | 9.8% | 9.7% |
| Return on capital | −26.4% | −12.6% | −6.7% | −6.7% | −4.6% | −1.3% | −111.8% | −6.9% | −36.0% | −12.5% |
| Return on equity | −36.2% | −27.0% | −12.3% | −9.8% | −5.7% | −2.7% | −148.8% | −9.5% | −52.5% | −13.9% |
| Return on assets | −27.8% | −18.9% | −8.2% | −6.3% | −5.0% | −2.4% | −123.7% | −5.0% | −25.3% | −6.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | 4.7x | — | 2.1x |